Email this article 
Post a Comment A new method for treatment severe forms of dry keratoconjunctivitis (preliminary results)
- Authors: Safonova T.N.1, Gladkova O.V.1, Novikov I.A.1, Boev V.I.1
-
Affiliations:
- Research Institute of Eye Diseases
- Issue: Vol 10, No 3 (2017)
- Pages: 53-59
- Section: Articles
- URL: https://journals.rcsi.science/ov/article/view/7195
- DOI: https://doi.org/10.17816/OV10353-59
- ID: 7195
Cite item
Full Text
Abstract
The aim is to improve the treatment method of severe keratoconjunctivitis sicca (KCS) forms using designed soft contact lenses (SCL).
Material and methods. An original SCL of silicone hydrogel material with individual optical power, consisting of a non-through depot filled with 0.05% Cyclosporin A (CyA) was designed. The therapeutic CyA saturated SCL was used in 5 patients (1 male and 4 females; 7 eyes) aged from 34 to 66 years, with severe KCS, who were constantly wearing them for 7-14 days. Patients additionally instilled hyaluronic acid containing non-preserved artificial tears up to 6 times a day. Standard ophthalmic examination, Schirmer test, tear break-up-time test, tests using vital dyes (assessed using the Oxford scale), tear osmolarity measurements (TearLab System, USA), tear pH measurement by a highly sensitive litmus test, conjunctival culture, measurement of the interpalpebral fissure width were carried out, the ocular surface disease index (OSDI) was determined. Treatment results were assessed in 1 week, 1 month, and 3 months since the SCL wear start.
Results. The use of therapeutic CyA saturated SCL allows to achieve complete corneal epithelization, and helps to reduce inflammation within the time from 1 week up to 1 month, significantly reducing the treatment timeframe of severe forms of KSC in comparison to standard therapy.
Conclusion.The developed treatment method for severe forms of the KCS consists in using specifically designed therapeutic SCL which provides an even CyA 0.05% release on the ocular surface, while instilling non-preserved artificial tears. Preliminary results show a high efficacy of this method in terms of reducing corneal epithelization time up to 1 week-1 month and resolving inflammation on the ocular surface.
Full Text
##article.viewOnOriginalSite##About the authors
Tatyana N. Safonova
Research Institute of Eye Diseases
Author for correspondence.
Email: Safotat@mail.ru
MD, PhD, leading researcher. Lacrimal apparatus pathology department
Russian Federation, MoscowOlga V. Gladkova
Research Institute of Eye Diseases
Email: Lykicheva_olga@mail.ru
MD, aspirant. Lacrimal apparatus pathology department
Russian Federation, MoscowIvan A. Novikov
Research Institute of Eye Diseases
Email: i.novikov@niigb.ru
senior scientist at the department of basic research in ophthalmology
Russian Federation, MoscowVasil I. Boev
Research Institute of Eye Diseases
Email: info@eyeacademy.ru
PhD, leading engineer at the department of refractive disorders
Russian Federation, MoscowReferences
- Брежский В.С., Калинина И.В. Комплексное лечение заболеваний роговицы ксеротического генеза // Клиническая офтальмология. – 2015. – № 3. – С. 159–165. [Brezhskij VS, Kalinina IV. Complex treatment of diseases of the cornea sclerotic origin. Klinicheskaja Oftal’mologija. 2015;(3):159-165. (In Russ.)]
- Гладкова О.В., Сафонова Т.Н., Боев В.И. Применение лечебных МКЛ на фоне местной иммуносупрессивной терапии у больных с сухим кератоконъюнктивитом аутоиммунного генеза. X Съезд офтальмологов России: сб. науч. тр. – М., 2015. – С. 51. [Gladkova OV, Safonova TN, Boev VI. The use of therapeutic soft contact lens against the background of the local immunosuppressive therapy in patients with dry keratoconjunctivitis autoimmune origin. (Conference proceedings) X S’’ezd oftal’mologov Rossii. Moscow; 2015. P. 51. (In Russ.)]
- Майчук Д.Ю., Вахова Е.С., Майчук Ю.Ф. Применение липосомальных глазных капель циклоспорина-циклолипа в лечении воспалительных заболеваний глаз // Новые лекарственные препараты. – 1998. – № 10. – С. 29–32. [Majchuk DJu, Vahova ES, Majchuk JuF. Application of liposomal cyclosporin eyedrops – tsiklolipa in treating inflammatory eye diseases. Novye lekarstvennye preparaty. 1998;(10):29-32. (In Russ.)]
- Патент РФ на изобретение RU № 2285511/ 13.10.2004. Яни Е.В., Майчук Д.Ю. Средство для лечения синдрома «сухого глаза». [Patent RUS No 2285511/ 13.10.2004. Jani EV, Majchuk DJu. The agent for the treatment of dry eye syndrome. (In Russ.)]
- Сафонова Т.Н., Гладкова О.В., Новиков И.А., Боев В.И. Новая модель лечебной мягкой контактной линзы // Материалы научной конференции офтальмологов «Невские горизонты-2016». – СПб., 2016. – С. 513–515. [Safonova TN, Gladkova OV, Novikov IA, Boev VI. The new model of therapeutic soft contact lenses. (Conference proceedings) Saint Petersburg; 2016. P. 513-515. (In Russ.)]
- Ankita S. Bhavsar, Samir G. Bhavsar, Sunita M. Jain. A review on recent advances in dry eye: Pathogenesis and management. Oman J Ophthalmol. 2011;4(2):50-56. doi: 10.4103/0974-620x.83653.
- Davis JL, Gilger BC, Robinson MR. Novel approaches to ocular drug delivery. Curr Opin Mol Ther. 2004;6 (2):195-205.
- Donnenfeld E, Plugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54(3):321-338. doi: 10.1016/j.survophthal.2009.02.002.5.
- Galante R, Paradiso P, Moutinho MG, Fernandes AI, et al. About the effect of eye blinking on drug release from pHEMA-based hydrogels: an in vitro study. J Biomater Sci Polym Ed. 2015;26(4):235-251. doi: 10.1080/09205063.2014.994948.
- Gupta C, Chauhan A. Ophthalmic delivery of cyclosporine A by punctal plugs. J Control Release. 2011;150(1):70-76. doi: 10.1016/j.jconrel.2010.11.009.
- Kim H, et al. Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. Investig Ophthalmol Vis Sci. 2005;46(2):655-662. doi: 10.1167/iovs.04-1076.
- Kymionis GD, Bouzoukis DI, Diakonis, VF, Siganos C. Treatment of chronic dry eye: focus on cyclosporine. Clin Ophthalmol. 2008;2(4):829-836. doi: 10.2147/opth.s1409.
- Peng СС, Kim J, Chauhan A. Extended delivery of hydrophilic drugs from silicone-hydrogel contact lenses containing vitamin E diffusion barriers. Biomaterials. 2010;31(14):4032-4047. doi: 10.1016/j.biomaterials.2010.01.113.
- Ragam A, Kolomeyer AM, Kim JS, et al. Topical cyclosporine a 1 % for the treatment of chronic ocular surface inflammation. Eye Contact Lens. 2014;40(5):283-288. doi: 10.1097/icl.0000000000000055.
- Sall K, Stevenson OD, Mundorf TK. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107(4):630-639. doi: 10.1016/s0161-6420(99)00176-1.
Supplementary files
